Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study
Titel:
Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study
Auteur:
Corrie, Pippa G Marshall, Andrea Dunn, Janet A Middleton, Mark R Nathan, Paul D Gore, Martin Davidson, Neville Nicholson, Steve Kelly, Charles G Marples, Maria Danson, Sarah J Marshall, Ernest Houston, Stephen J Board, Ruth E Waterston, Ashita M Nobes, Jenny P Harries, Mark Kumar, Satish Young, Gemma Lorigan, Paul
Verschenen in:
Lancet oncology
Paginering:
Jaargang 15 (2014) nr. 6 pagina's 620-630
Jaar:
2014
Inhoud:
Uitgever:
Corrie et al. Open Access article distributed under the terms of CC BY